Physician profile
Michael Seibert
NPI 1134380298
$6,173.50
in general payments reported to CMS, 2019-2025
20 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $787 · 2021: $734 · 2022: $960 · 2023: $1,341 · 2024: $1,111 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681 · Education: $10.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,681.13 |
| Education | $10.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,249.79 | 2020-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,646.28 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $605.60 | 2020-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $463.35 | 2020-2023 | Symtuza |
| Theratechnologies INC. | $398.81 | 2020-2024 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $148.33 | 2020-2024 | Mytesi |
| Abbvie INC. | $124.58 | 2025 | |
| Emd Serono, INC. | $114.48 | 2022-2025 | Serostim |
| Antares Pharma, INC. | $103.07 | 2020-2023 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $64.99 | 2022-2023 | Shingrix, Arexvy |
| Hologic Sales and Service, LLC | $62.98 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Lilly USA, LLC | $30.09 | 2025 | Zepbound, Mounjaro |
| Alkermes, INC. | $28.48 | 2025 | Vivitrol |
| Eisai INC. | $24.43 | 2020 | |
| Redhill Biopharma INC. | $23.67 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $20.57 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.82 | 2024 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $17.02 | 2021 | |
| Endo Pharmaceuticals INC. | $16.42 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Seibert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.